| Document |
Document Title |
|
JP2022512874A |
The present invention relates to the field of medicine, especially cancer treatment. More specifically, the invention relates to novel compounds typically for use as pharmaceuticals. In particular, the invention presents presentation of ...
|
|
JP7004706B2 |
The present specification relates to a novel quercetin-based compound separated from post fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, the compound being capable of...
|
|
JP2022509174A |
The present invention comprises compounds or pharmaceutically acceptable polymorphs, solutes, mirror isomers, steric isomers and hydrates thereof, and effective amounts of compounds of Formula I, Formula II, Formula III and Formula IV. W...
|
|
JP2022507776A |
A 13-member macrolide for the treatment of infectious diseases is provided. The 13-member macrolide described herein is an azake ketolide. There are also methods of preparing 13-membered macrolides, pharmaceutical compositions containing...
|
|
JP2022507795A |
A 13-member macrolide for the treatment of infectious diseases will be provided. The 13-member macrolides described herein are azaquetlides. Also provided is a method for producing the 13-membered macrolide, a pharmaceutical composition ...
|
|
JP2022505463A |
The present invention relates to compounds useful as therapeutic agents for cancer. The compound comprises an azithromycin derivative having a phosphonium cation moored to the azithromycin macrocyclic molecule. The present invention also...
|
|
JP6991142B2 |
The present invention provides a 6-acyl-2-O-α-D-glycosyl-L-ascorbic acid represented by general formula (3) (in the formula, n denotes an integer of 1 or higher and R denotes a hydrocarbon group) and/or a composition containing this com...
|
|
JP2021536462A |
Derivatives of AmB characterized by improved clinical efficacy and reduced toxicity as compared to amphotericin B (AmB) are disclosed. Also disclosed are pharmaceutical compositions containing AmB derivatives, therapeutic methods using A...
|
|
JP2021193088A |
To provide tiacumicin compounds and dosage regimen for use in the oral treatment of Clostridium difficile infections (CDI) or Clostridium difficile-associated disease (CDAD).The invention provides one or more tiacumicin compounds, a ster...
|
|
JPWO2020170840A1 |
The subject was to provide a novel crystal of 2-O-α-D-glucosyl-L-ascorbic acid and a method for producing the same, and the crystal of the potassium salt of 2-O-α-D-glucosyl-L-ascorbic acid. The above problem is solved by providing the...
|
|
JP2021535080A |
In the present invention, the formula I [in the formula, n = 0 to 5, and X = NH, O, S, CH2Y = phenyl, at least one methyl substituted phenyl group, at least one nitro substituted phenyl group, at least one nitrogen substituted phenyl gro...
|
|
JP2021534178A |
The present invention is to obtain substituted pyrazole compounds, methods for preparing them, pharmaceutical compositions and uses. The compound has good stability, excellent solubility, low toxicity to cells, remarkable protective effe...
|
|
JP6978492B2 |
Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
|
|
JP6961100B2 |
The present invention relates to a composition comprising an anthocyanin-fucoidan complex formed by ionic bond between anthocyanin and fucoidan as an active ingredient, and more particularly, it is confirmed that the anthocyanin-fucoidan...
|
|
JP6945864B2 |
The present invention generally relates to systems and methods for pressure driven flow crystallization. In some embodiments, the system comprises a comprising a cavity and a mixing mechanism. In some embodiments, one or more inlets faci...
|
|
JP6945042B2 |
To provide sesaminol disaccharide or trisaccharide glycosides, and a method for producing the same.Sesaminol 2'-O-β-D-glucosyl (1→2)-O-[β-D-glucosyl (1→2)].SELECTED DRAWING: None
|
|
JPWO2020085459A1 |
It is an object of the present invention to provide a more potent antioxidant, anti-glycation agent and anti-inflammatory agent as an alternative to an imidazole-containing dipeptide. The present invention relates to an antioxidant, an a...
|
|
JPWO2020090813A1 |
An extraction step in which a lottery containing flavonoids is brought into contact with a lottery containing liquefied dimethyl ether to extract an extract containing flavonoids, and at least a part of the extract is vaporized and remov...
|
|
JP2021524439A |
Provided are biarylamide and coumarin-based compounds with modified glycosyl for the treatment of diseases associated with the heat shock protein pathway. The compound has the following formulas (I), (II), (III), (IV), and (V), and the v...
|
|
JPWO2020040233A1 |
Provided is a method for obtaining a crystal having a specific shape of a compound (particularly a spherulite) with good reproducibility. A method for producing a crystal having a specific shape of a compound (particularly a spherical cr...
|
|
JP6923100B1 |
To provide a novel active ingredient derived from carob and its use. The present invention is a compound represented by the following formula (I), a salt thereof, or a solvate thereof.[Selection diagram] None
|
|
JP6902757B2 |
The present invention relates to dicaffeoyl spermidine cyclized derivatives and a preparation method and use thereof. Biological activity experiments show that the dicaffeoyl spermidine cyclized derivatives of the present invention have ...
|
|
JP6895436B2 |
Provided are a metal salt of 2-O-α-D-glycosyl-L-ascorbic acid represented by general formula (1) (in the formula, n denotes an integer of 1 or higher), an amorphous powder thereof, and a method for producing same. Also provided is an an...
|
|
JP6887022B2 |
A process for preparing ketolide compounds is disclosed. (Formula I) (I)
|
|
JP6881308B2 |
A production method for producing an aldehyde compound or a ketone compound by oxidizing a primary or secondary alcohol compound, wherein the alcohol compound has, in the molecule thereof, a group selected from an amino group, an azide g...
|
|
JP6878608B2 |
The present invention relates to novel compounds useful for visualizing cell senescence in vitro and in vivo, the preparation of said compounds and their use. In particular, the present invention pertains to novel hexose and particularly...
|
|
JP2021075570A |
To provide amphotericin B (AmB) as a form or a derivative that is effective against fungal infections and less toxic.The invention provides a compound represented by a formula (I) in the figure or a pharmacologically acceptable salt ther...
|
|
JP2021073200A |
To provide novel carrier compositions for efficiently delivering a therapeutic agent, diagnostic agent, or targeting agent to a therapeutic site, in the treatment of diseases such as cancer, or in vivo diagnosis.Provided is a carrier com...
|
|
JP6850783B2 |
Provided herein are methods of preparing macrolides by the coupling of an eastern and western half, followed by macrocyclization, to provide macrolides, including both known and novel macrolides. Intermediates in the synthesis of macroli...
|
|
JP6849896B2 |
The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention fur...
|
|
JP6849983B2 |
It is an object of the present invention to provide a fluorescence imaging probe capable of selectively visualizing target cells such as cells expressing β-galactosidase (lacZ expressing cells) at a single-cell level in a red fluorescen...
|
|
JP6843874B2 |
This invention is based on the discovery that homogeneous catalysts, [Rh(C2H4)2Cl]2 and/or [Rh(COD)2][BF4], can be used to produce spinetoram in higher yields at lower catalyst loadings as compared to previous methodologies. In addition,...
|
|
JP6839494B2 |
To provide novel flavonoid glycosides, production methods thereof, and physiological applied products of novel flavonoid glycosides.The present invention provides an α mono-glucosyl rhoifolin, and the following production method, as wel...
|
|
JP6824521B2 |
To provide a new plant-derived compound having muscle differentiation and/or bone differentiation promoting action.The present invention provides a compound represented by formula (1), salt thereof or ester thereof. The compound can be o...
|
|
JP6808334B2 |
To overcome problem such as flavor where an enzyme treated article of rutin is largely manufactured by an enzyme treatment using rutin purified from plants as a raw material and rutin having different purity or containing impurities such...
|
|
JP2020196704A |
To provide a novel medicine for preventing and/or treating influenza virus infection or corona virus infection.According to the present invention, provided are an anti-influenza virus agent, an anti-corona virus agent and a prophylactic ...
|
|
JP6797126B2 |
The present invention relates to a quinoline derivative of formula (1) or one of its pharmaceutically acceptable salts. The present invention further relates to said quinoline derivative for use as a medicament and for use in the treatme...
|
|
JP6784942B2 |
The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders.
|
|
JP2020172517A |
To provide a crystalline form of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, and a production method.A crystalline 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide form has the following characteristics: an FT-Raman spectrum comprising...
|
|
JP2020172516A |
To provide a crystalline form of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, and a production method.A crystalline 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide form has the following characteristics: an FT-Raman spectrum comprising...
|
|
JP6773672B2 |
Processes and intermediates for preparing fluoroketolide compounds are described herein.
|
|
JP6755859B2 |
Disclosed is a simplified, readily scalable series of individual methods that collectively constitute a method for the synthesis of C2′epiAmB, an efficacious and reduced-toxicity derivative of amphotericin B (AmB), beginning from AmB. ...
|
|
JP6751868B2 |
To provide an ascorbic acid derivative of high purity 2-o-glucopyranosyl-3-o-ether bond type and a use thereof.According to the present invention, there are provided an ascorbic acid derivative of high purity 2-o-glucopyranosyl-3-o-ether...
|
|
JP6741315B2 |
The invention discloses an esculin hydrate thioctic ester compound with antioxidant activity, and a preparation method thereof. According to the preparation method, esculin hydrate and thioctic acid are taken as raw materials, in an orga...
|
|
JP6726192B2 |
Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives and C16 carbamate derivatives of AmB. Also provided are met...
|
|
JP2020517749A |
The present invention relates to compounds useful as cancer treatments. Compounds include azithromycin derivatives having a phosphonium cation linked to an azithromycin macrocycle. The present invention also relates to a method of using ...
|
|
JP2020090675A |
To provide methods for the treatment of an inflammation caused by polymicrobial infections, and sepsis and severe sepsis, SIRS and septic shock.The present invention provides a composition containing chitin and chitosan derivatives as an...
|
|
JP2020515559A |
Compounds that regulate CD73 activity, pharmaceutical compositions containing said compounds, and methods of using said compounds for treating diseases associated with CD73 activity are described herein. [Selection diagram] None
|
|
JP2020513012A |
The art relates to compounds (eg, avermectin derivatives), compositions, and methods associated with the regulation of FXR. In particular, the compounds and compositions are FXR-mediated, including, for example, liver disease, hyperlipid...
|
|
JP6675973B2 |
The invention described herein relates to processes for preparing ketolide antibacterial agents. In particular, the invention relates to intermediates and processes for preparing ketolides that include a 1,2,3-triazole substituted side c...
|
